Suppr超能文献

早期哮喘预防、自然病史、骨骼发育与经济(EASE):一项随机对照试验试点研究

Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.

作者信息

Baxter-Jones A D, Helms P J, Russell G, Grant A, Ross S, Cairns J A, Ritchie L, Taylor R, Reid D M, Osman L M, Robins S, Fletcher M E

机构信息

Department of Child Health, University of Aberdeen, UK.

出版信息

Health Technol Assess. 2000;4(28):1-89.

Abstract

OBJECTIVES

(1) To establish recruitment rates of newly presenting asthmatic children. (2) To establish acceptability of study protocols. (3) To pilot age-specific quality of life (QoL) assessment. (4) To assess short-term (6 months) outcomes of inhaled corticosteroids (ICS) treatment. (5) To refine sample size calculations for a definitive study.

DESIGN

A randomised pragmatic longitudinal trial design was used, with no blinding or placebo, to examine early ICS introduction similar to its use in practice. Subjects were assessed at entry, 3 and 6 months.

SETTING

Subjects were recruited from six general practices. Children under 6 years were assessed at the Craig Research and Investigation Unit, Royal Aberdeen Children's Hospital, or their family home, and subjects 6 years and over were assessed at their general practice.

SUBJECTS

Children (aged 6 months-16 years) with symptoms suggestive of asthma/wheeze that had commenced no longer than 12 months before were identified retrospectively and prospectively from general practices. Subjects were also required to be naïve to prophylactic therapy with no other lung disease/concomitant illness.

INTERVENTIONS

Subjects were randomised to ss2-agonist (ss2-only group) or ss2-agonist and ICS (ICS group) for 6 months. Physicians could later prescribe ICS in controls if needed.

MAIN OUTCOME MEASURES

(1) Pulmonary function. (2) Asthma symptom diary. (3) Symptomatic health status questionnaire. (4) Caregiver's and child's QoL. (5) Growth. (6) Bone mass. (7) Bone turnover. (8) Economic issues.

RESULTS

Of over 15,000 children yielded from general practice records, 11% had symptoms suggestive of asthma/wheeze, and two-thirds of these already used ICS. Of the remaining, 141 subjects met the criterion of early asthma, and 86 were randomised. Two-thirds of those randomised were < 6 years old, the males:females ratio was 2:1, and 67% had a family history of atopy. RESULTS - PHYSIOLOGICAL DEVELOPMENT: Pulmonary function did not significantly improve in the older children. Although tidal breathing measures in the pre-school children were significantly higher at 6 months in the ss2-only group, there was great variability. Incidence of wheeze and night-time cough reduced equally in both groups. Reduction of night-time symptom score and reliever use, and increase in symptom-free days were only significant in the ss2-only group. No significant differences were found in growth and bone mass between the two groups, but bone metabolism was significantly reduced at 6 months in the ICS group. RESULTS - PSYCHOLOGICAL DEVELOPMENT: The caregiver's QoL questionnaire was sensitive to child symptom changes over 3 months, but absolute impact of child symptoms on their QoL varied, whereas the child-centred questionnaire was not sensitive to change. RESULTS - ECONOMICS: There were no significant differences in medical consultation costs between the groups, but, as expected, prescription costs in the ICS group were higher over 6 months. Combined healthcare costs were significantly higher for patients assigned to ICS, but there were no significant differences in any effectiveness measures between the groups.

CONCLUSIONS

Most (96%) of the proposed sample was recruited, and the low drop-out rate (8%) demonstrated acceptability of the study protocol. Most children first presenting with symptoms suggestive of asthma were < 6 years old and represented a group biased towards mild to moderate asthma, or virally induced wheeze. The caregiver's QoL questionnaire was found to better reflect a child's symptom changes than a child-centred instrument. In the short term, no adverse effects were seen on growth, but ICS treatment significantly reduced bone metabolism. Most of the young children with asthma/wheeze improved over time with ss2-agonist treatment alone, and clinical benefits of early ICS intervention amongst these children were not detected; however, there was inadequate power in this pilot study to establish this. (AB

摘要

目的

(1)确定新出现的哮喘儿童的招募率。(2)确定研究方案的可接受性。(3)试行针对不同年龄段的生活质量(QoL)评估。(4)评估吸入性糖皮质激素(ICS)治疗的短期(6个月)结果。(5)为确定性研究优化样本量计算。

设计

采用随机实用纵向试验设计,不设盲法或安慰剂,以研究早期引入ICS在实际应用中的情况。在入组时、3个月和6个月时对受试者进行评估。

设置

受试者从六个全科医疗诊所招募。6岁以下儿童在阿伯丁皇家儿童医院克雷格研究与调查单元或其家中接受评估,6岁及以上受试者在其全科医疗诊所接受评估。

受试者

回顾性和前瞻性地从全科医疗诊所中识别出年龄在6个月至16岁之间、有哮喘/喘息症状且症状出现不超过12个月的儿童。受试者还需未曾接受过预防性治疗且无其他肺部疾病/合并症。

干预措施

受试者被随机分为短效β2受体激动剂组(仅使用短效β2受体激动剂组)或短效β2受体激动剂加ICS组(ICS组),为期6个月。如有需要,医生可在对照组中随后开具ICS处方。

主要观察指标

(1)肺功能。(2)哮喘症状日记。(3)症状性健康状况问卷。(4)照顾者和儿童的生活质量。(5)生长情况。(6)骨量。(7)骨转换。(8)经济问题。

结果

从全科医疗记录中筛选出的15000多名儿童中,11%有哮喘/喘息症状,其中三分之二已在使用ICS。其余儿童中,141名符合早期哮喘标准,86名被随机分组。随机分组的儿童中三分之二年龄小于6岁,男女比例为2:1,67%有特应性家族史。结果 - 生理发育:年龄较大的儿童肺功能没有显著改善。虽然仅使用短效β2受体激动剂组学龄前儿童的潮式呼吸指标在6个月时显著更高,但个体差异很大。两组喘息和夜间咳嗽的发生率均同等降低。夜间症状评分和缓解药物使用的减少以及无症状天数的增加仅在仅使用短效β2受体激动剂组中显著。两组在生长和骨量方面未发现显著差异,但ICS组在6个月时骨代谢显著降低。结果 - 心理发育:照顾者生活质量问卷对儿童症状在3个月内的变化敏感,但儿童症状对其生活质量的绝对影响各不相同,而以儿童为中心的问卷对变化不敏感。结果 - 经济学:两组之间的医疗咨询费用没有显著差异,但正如预期的那样,ICS组在6个月内的处方费用更高。分配到ICS组的患者综合医疗费用显著更高,但两组在任何有效性指标上均无显著差异。

结论

拟招募样本的大部分(96%)已被招募,低退出率(8%)表明研究方案具有可接受性。大多数首次出现哮喘症状的儿童年龄小于6岁,代表了一组偏向轻度至中度哮喘或病毒诱导喘息的人群。发现照顾者生活质量问卷比以儿童为中心的工具能更好地反映儿童症状变化。短期内,未观察到对生长有不良影响,但ICS治疗显著降低了骨代谢。大多数患有哮喘/喘息的幼儿仅通过短效β2受体激动剂治疗随时间推移有所改善,未检测到这些儿童早期ICS干预的临床益处;然而,该试点研究的效能不足以确定这一点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验